<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>中睿医药评论 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-26T20:17:43+08:00</updated>
  <subtitle>中睿咨询致力于帮助中国本土大中型企业和具备核心资源的中小成长型企业构建企业战略和战术落地高度融合的一体化的体系。推动企业在明确战略方向指引下，实现持续成长！</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>高达7.68亿美元！复宏汉霖授权靶向EGFR和4-1BB的双特异性抗体海外权益</title>
    <updated>2020-11-26T16:55:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/2m1t1LHy-XeiflNM6VNQZg</id>
    <link href="https://mp.weixin.qq.com/s/2m1t1LHy-XeiflNM6VNQZg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重磅！恒瑞医药卡瑞利珠单抗+苹果酸法米替尼被纳入拟突破性治疗品种公示</title>
    <updated>2020-11-26T16:55:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-26:/s/SU52M_RiPp04D2A67RM3cA</id>
    <link href="https://mp.weixin.qq.com/s/SU52M_RiPp04D2A67RM3cA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国产「药王」新适应症获批，八成原研市场进一步被瓜分</title>
    <updated>2020-11-25T17:28:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/mOp1zmpKsrTRqATdIustvg</id>
    <link href="https://mp.weixin.qq.com/s/mOp1zmpKsrTRqATdIustvg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>正大天晴「注射用泮托拉唑钠」集齐4家！另有四川科伦、常州康普、扬子江等药企过评</title>
    <updated>2020-11-25T17:28:35+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-25:/s/9nrU0UDECU7SbCRxN8wM2Q</id>
    <link href="https://mp.weixin.qq.com/s/9nrU0UDECU7SbCRxN8wM2Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州进入密集收获期，多款创新药迎来新进展...</title>
    <updated>2020-11-24T18:32:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/TbgAusYmnheFlKUIRVbjRw</id>
    <link href="https://mp.weixin.qq.com/s/TbgAusYmnheFlKUIRVbjRw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>豪森2款仿制药品种报产</title>
    <updated>2020-11-24T18:32:49+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-24:/s/RO4MSjj3k1g7OVYfsST4PA</id>
    <link href="https://mp.weixin.qq.com/s/RO4MSjj3k1g7OVYfsST4PA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>最新！2020年全球医疗器械企业100强出炉！</title>
    <updated>2020-11-23T17:39:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/p5lADDQyMEETZxzquWO93w</id>
    <link href="https://mp.weixin.qq.com/s/p5lADDQyMEETZxzquWO93w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>多款新冠mRNA疫苗迎重要进展；FDA批准首个早衰症疗法</title>
    <updated>2020-11-23T17:39:24+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-23:/s/VYDPhsM-0pEwEGKYOurfFg</id>
    <link href="https://mp.weixin.qq.com/s/VYDPhsM-0pEwEGKYOurfFg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>先声药业引进的1类新药获批临床，针对痛风伴高尿酸血症！</title>
    <updated>2020-11-20T15:00:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/ozKPzMser7IBCmunOQ6JuA</id>
    <link href="https://mp.weixin.qq.com/s/ozKPzMser7IBCmunOQ6JuA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>7款药物纳入第三批临床急需境外新药名单</title>
    <updated>2020-11-20T15:00:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/ZekMNaIIJ2tJ9a1_us2MDg</id>
    <link href="https://mp.weixin.qq.com/s/ZekMNaIIJ2tJ9a1_us2MDg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>刚刚！贝达药业「恩莎替尼」获批上市，首个国产 ALK 抑制剂</title>
    <updated>2020-11-19T17:16:25+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-19:/s/lyl6SHl1BZot9SQlBh1rPw</id>
    <link href="https://mp.weixin.qq.com/s/lyl6SHl1BZot9SQlBh1rPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球规模60亿美元，先声药业1.7亿美元引进的CDK 4/6抑制剂临床申请获受理！</title>
    <updated>2020-11-18T17:19:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/RRtl-HmT8jR2pi2CieZWGg</id>
    <link href="https://mp.weixin.qq.com/s/RRtl-HmT8jR2pi2CieZWGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第三十五批参比目录公示：27个新增，15个增补，9个不通过</title>
    <updated>2020-11-18T17:19:53+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/glX8LstwSgKr_jtqW9SArg</id>
    <link href="https://mp.weixin.qq.com/s/glX8LstwSgKr_jtqW9SArg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州拟赴科创板上市，预计将于2021年上半年完成！</title>
    <updated>2020-11-16T17:22:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/2wfPKNC64ypHf4PqPTESnw</id>
    <link href="https://mp.weixin.qq.com/s/2wfPKNC64ypHf4PqPTESnw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>扬子江「恩替卡韦口服溶液」即将获批</title>
    <updated>2020-11-16T17:22:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-16:/s/yEDWrh7jjxLmgf8OWh_Zew</id>
    <link href="https://mp.weixin.qq.com/s/yEDWrh7jjxLmgf8OWh_Zew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>恒瑞、贝达临床试验丨复星疫苗注册受理丨科伦新药注册+仿制药一致性评价</title>
    <updated>2020-11-13T17:25:36+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-13:/s/o27zqXp34yJy29d_JW2LWg</id>
    <link href="https://mp.weixin.qq.com/s/o27zqXp34yJy29d_JW2LWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>“首仿王”正大天晴再下一城，拿下泊马度胺首仿！</title>
    <updated>2020-11-12T17:28:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/ILJiJ4r5ikih0R4UdEMqqA</id>
    <link href="https://mp.weixin.qq.com/s/ILJiJ4r5ikih0R4UdEMqqA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>豪森药业「注射用替加环素」首家通过一致性评价</title>
    <updated>2020-11-12T17:28:20+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-12:/s/8QoUIJCeYLySN6KXqOudPg</id>
    <link href="https://mp.weixin.qq.com/s/8QoUIJCeYLySN6KXqOudPg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>